Suzanne Tran, Alice Thomas, Ilyes Aliouat, Carine Karachi, Fernando Lozano, Karima Mokhtari, Caroline Dehais, Loïc Feuvret, Catherine Carpentier, Marine Giry, Habiba Doukani, Julie Lerond, Yannick Marie, Marc Sanson, Ahmed Idbaih, Alexandre Carpentier, Khê Hoang-Xuan, Mehdi Touat, Laurent Capelle, Franck Bielle
AIMS: The distinction between CNS WHO grade 2 and grade 3 is instrumental in choosing between observational follow-up and adjuvant treatment for resected astrocytomas IDH-mutant. However, the criteria of CNS WHO grade 2 versus 3 have not been updated since the pre-IDH era. METHODS: Maximal mitotic activity in consecutive high-power fields corresponding to 3 mm2 was examined for 118 lower-grade astrocytomas IDH-mutant. The prognostic value for time-to-treatment (TTT) and overall survival (OS) of mitotic activity and other putative prognostic factors (including age, performance status, pre-surgical tumour volume, multilobar involvement, post-surgical residual tumour volume, midline involvement) was assessed for tumours with ATRX loss and the absence of CDKN2A homozygous deletion or CDK4 amplification, contrast enhancement, histological necrosis, and microvascular proliferation...
July 28, 2023: Neuropathology and Applied Neurobiology